Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database

Abstract Background Neuroblastoma is a common extracranial malignant tumor in children. Its main treatment modality is a combination of chemotherapy, radiotherapy, and surgery. Given the advances in chemotherapy regimens and the widespread use of bone marrow transplantation over the decades, there h...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hongnan Zhen, Hui Guan, Jiabin Ma, Wenhui Wang, Shen Jing, Zheng Miao, Fuquan Zhang, Zhikai Liu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Neuroblastoma Second malignant neoplasms Survival rate Radiotherapy Chemotherapy Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/57912aa0caaf459db57419963594a260
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57912aa0caaf459db57419963594a260
record_format	dspace
spelling	oai:doaj.org-article:57912aa0caaf459db57419963594a2602021-11-28T12:13:58ZRisk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database10.1186/s13014-021-01943-x1748-717Xhttps://doaj.org/article/57912aa0caaf459db57419963594a2602021-11-01T00:00:00Zhttps://doi.org/10.1186/s13014-021-01943-xhttps://doaj.org/toc/1748-717XAbstract Background Neuroblastoma is a common extracranial malignant tumor in children. Its main treatment modality is a combination of chemotherapy, radiotherapy, and surgery. Given the advances in chemotherapy regimens and the widespread use of bone marrow transplantation over the decades, there has been improvement in treatment efficacy, which has led to prolonged patient survival. Accordingly, long-term complications have become a growing concern among physicians and patients. This study aimed to analyze the survival rate of patients with neuroblastoma and the risk factors for developing second malignant neoplasms (SMNs). Methods The SEER 18 Regs (1973–2015) and SEER 9 Regs (1973–2015) data of the surveillance, epidemiology, and end results (SEER) database of the US National Cancer Institute were adopted for survival and SMN analysis. Results The 5-, 10-, and 20-year overall survival rates of patients with neuroblastoma were 67%, 65%, and 62%, respectively. Among 38 patients with neuroblastoma who presented with SMNs, those with abdomen as the primary site accounted for the majority (63.2%), followed by those with thorax (26.3%) and other sites (10.5%). SMNs occurred more commonly in non-specific neuroblastoma (incidence: 0.87%) than ganglioneuroblastoma (incidence: 0.3%). Compared with the general population, the risk of SMN is significantly higher (SIR = 4.36). The risk of developing SMNs was significantly higher in the digestive system (SIR = 7.29), bones and joints (SIR = 12.91), urinary system (SIR = 23.48), brain and other nervous systems (SIR = 5.70), and endocrine system (SIR = 5.84). Multivariate analysis revealed that the year of diagnosis (OR = 2.138, 95% CI = 1.634–2.797, p < 0.001) was the only independent risk factor for developing SMNs. Conclusion This study identifies the risk factor for developing SMNs in patients with neuroblastoma, which could facilitate individualized screening for high-risk patients, to allow early diagnosis and treatment of SMNs.Hongnan ZhenHui GuanJiabin MaWenhui WangShen JingZheng MiaoFuquan ZhangZhikai LiuBMCarticleNeuroblastomaSecond malignant neoplasmsSurvival rateRadiotherapyChemotherapyMedical physics. Medical radiology. Nuclear medicineR895-920Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENRadiation Oncology, Vol 16, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neuroblastoma Second malignant neoplasms Survival rate Radiotherapy Chemotherapy Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neuroblastoma Second malignant neoplasms Survival rate Radiotherapy Chemotherapy Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hongnan Zhen Hui Guan Jiabin Ma Wenhui Wang Shen Jing Zheng Miao Fuquan Zhang Zhikai Liu Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database
description	Abstract Background Neuroblastoma is a common extracranial malignant tumor in children. Its main treatment modality is a combination of chemotherapy, radiotherapy, and surgery. Given the advances in chemotherapy regimens and the widespread use of bone marrow transplantation over the decades, there has been improvement in treatment efficacy, which has led to prolonged patient survival. Accordingly, long-term complications have become a growing concern among physicians and patients. This study aimed to analyze the survival rate of patients with neuroblastoma and the risk factors for developing second malignant neoplasms (SMNs). Methods The SEER 18 Regs (1973–2015) and SEER 9 Regs (1973–2015) data of the surveillance, epidemiology, and end results (SEER) database of the US National Cancer Institute were adopted for survival and SMN analysis. Results The 5-, 10-, and 20-year overall survival rates of patients with neuroblastoma were 67%, 65%, and 62%, respectively. Among 38 patients with neuroblastoma who presented with SMNs, those with abdomen as the primary site accounted for the majority (63.2%), followed by those with thorax (26.3%) and other sites (10.5%). SMNs occurred more commonly in non-specific neuroblastoma (incidence: 0.87%) than ganglioneuroblastoma (incidence: 0.3%). Compared with the general population, the risk of SMN is significantly higher (SIR = 4.36). The risk of developing SMNs was significantly higher in the digestive system (SIR = 7.29), bones and joints (SIR = 12.91), urinary system (SIR = 23.48), brain and other nervous systems (SIR = 5.70), and endocrine system (SIR = 5.84). Multivariate analysis revealed that the year of diagnosis (OR = 2.138, 95% CI = 1.634–2.797, p < 0.001) was the only independent risk factor for developing SMNs. Conclusion This study identifies the risk factor for developing SMNs in patients with neuroblastoma, which could facilitate individualized screening for high-risk patients, to allow early diagnosis and treatment of SMNs.
format	article
author	Hongnan Zhen Hui Guan Jiabin Ma Wenhui Wang Shen Jing Zheng Miao Fuquan Zhang Zhikai Liu
author_facet	Hongnan Zhen Hui Guan Jiabin Ma Wenhui Wang Shen Jing Zheng Miao Fuquan Zhang Zhikai Liu
author_sort	Hongnan Zhen
title	Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database
title_short	Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database
title_full	Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database
title_fullStr	Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database
title_full_unstemmed	Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database
title_sort	risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the us seer database
publisher	BMC
publishDate	2021
url	https://doaj.org/article/57912aa0caaf459db57419963594a260
work_keys_str_mv	AT hongnanzhen riskofdevelopingsecondmalignantneoplasmsinpatientswithneuroblastomaapopulationstudyoftheusseerdatabase AT huiguan riskofdevelopingsecondmalignantneoplasmsinpatientswithneuroblastomaapopulationstudyoftheusseerdatabase AT jiabinma riskofdevelopingsecondmalignantneoplasmsinpatientswithneuroblastomaapopulationstudyoftheusseerdatabase AT wenhuiwang riskofdevelopingsecondmalignantneoplasmsinpatientswithneuroblastomaapopulationstudyoftheusseerdatabase AT shenjing riskofdevelopingsecondmalignantneoplasmsinpatientswithneuroblastomaapopulationstudyoftheusseerdatabase AT zhengmiao riskofdevelopingsecondmalignantneoplasmsinpatientswithneuroblastomaapopulationstudyoftheusseerdatabase AT fuquanzhang riskofdevelopingsecondmalignantneoplasmsinpatientswithneuroblastomaapopulationstudyoftheusseerdatabase AT zhikailiu riskofdevelopingsecondmalignantneoplasmsinpatientswithneuroblastomaapopulationstudyoftheusseerdatabase
_version_	1718408140395905024

Risk of developing second malignant neoplasms in patients with neuroblastoma: a population study of the US SEER database

Ejemplares similares